Hiv, Mental Health Wellness 1, Sexually Transmitted Diseases
Conditions
Brief summary
Despite the significant preventive efforts to reduce HIV infections in the past decades, the incidence in MSM has plateaued at a higher level after the turn of the millennium. In 2015 a reduction in newly diagnosed HIV cases was reported for the first time. Early detection of HIV and treatment as prevention may have played a positive role in reducing HIV transmission, however, numbers increased again in 2016. Over 90% of HIV positive MSM in Norway are treated and virologically suppressed and thereby considered not infectious. Since the early days of the HIV epidemic, changes in sexual behaviour and increased use of condoms have been advocated and the only tools available to prevent HIV transmission. Later, frequent testing and treatment of STIs (including HIV) have been added to the preventive measures available. Still, this does not seem to be sufficient for all MSM. The use of PrEP is therefore likely an important supplement to prevent HIV infections in MSM at high risk for HIV acquisition. The main objective of this study is to monitor the impact of PrEP on the subject's psychological and sexual health. It is also important to monitor the adherence to PrEP, development of drug resistance (in the case of undetected HIV infection at initiation of PrEP), frequency of other STIs, changes in sexual behaviour, recreational drug use and quality of life. PrEP has proven to be effective in reducing the sexual acquisition of HIV, however this requires that the medication is taken as prescribed, whilst the subject is exposed to high risk of infection.
Detailed description
This study is designed to evaluated implementation of PrEP treatment as a part of the general HIV preventive program in Norway. The target groups are mainly MSM and transgender persons at high risk of HIV infection, as well as other subjects at risk of HIV infection due to their sexual practices. Objectives include assessment of the following: 1. Assess the impact of PrEP on the sexual and psychological health of PrEP users Incidence of sexually transmitted infections (STIs) in PrEP users compared to those not taking PrEP 2. Assessment of drug compliance 3. Incidence of HIV seroconversion despite PrEP 4. Frequency and development of drug resistance in subjects who HIV-seroconvert (if any)
Interventions
None listed
Sponsors
Oslo University Hospital
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Male, female or transgender persons aged ≥ 18 years who are offered or have started PrEP in routine clinical practice, and 2, 3, 4, 5, 6 or 7 (below). 2. Men who have sex with men (MSM) and transgender persons; 1. who have had unprotected anal sex with two or more partners during the last six months and/or 2. who have had bacterial sexually transmittable infection(s) during the last twelve months and/or 3. who have used post-exposure prophylaxis(PEP) during the last twelve months and/or 4. who use recreational drugs when having sex 3. Indication for PrEP is present according to the assessment of the health care provider 4. Men and women who are at high risk of HIV according to their sexual practices 5. HIV-negative partner of a HIV-positive person not yet virologically suppressed by antiretroviral therapy (ART) 6. Sex workers with inconsistent condom use 7. Persons with inconsistent condom use with sexual partners in / from countries with a high prevalence of HIV (COHP)
Exclusion criteria
1. HIV positive subjects 2. Subjects who cannot take Emtricitabine/tenofovir disoproxil combination tablet (FTC/TDF) due to contraindications
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Impact of PrEP | 24 months | Assess the impact of PrEP on the sexual and psychological health of PrEP users |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of STIs | 24 months | Incidence of sexually transmitted infections (STIs) in PrEP users compared to those not taking PrEP |
| Drug compliance | 24 months | Assessment of drug compliance |
| HIV seroconversion | 24 months | Incidence of HIV seroconversion despite PrEP |
| Drug resistance | 24 months | Frequency and development of drug resistance in subjects who HIV-seroconvert |
Countries
Norway
Contacts
Primary ContactJorge Johansen
Backup ContactFrank O Pettersen
Outcome results
None listed